François Vandenesch was invited to the 45th RICAI (Interdisciplinary Meeting on Anti-Infective Chemotherapy) to present the results of the RHU IDBIORIV project — from the analytical validation of 2,000 isolates provided by the National Reference Center for antibiotic resistance, tested in 3,000 artificial blood cultures, to the initial findings from the clinical study conducted on real patients. The outstanding results highlight the value of the Weezion dx solution and mark a major milestone toward its future commercialization.
